5-Nov-2025 3:05 PM CST - Business Wire Biote Reports Third Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners patients, today announced financial results for the third quarter ended September 30, 2025. When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate growth from new providers, maximize value from our top-tier clinics, and improve our financial performance through gre
22-Oct-2025 3:05 PM CST - Business Wire Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call m
6-Aug-2025 3:05 PM CST - Business Wire Biote Reports Second Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2025. Consistent with our action plan to drive structural and cultural change, Biote initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable
23-Jul-2025 3:05 PM CST - Business Wire Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call ma
7-May-2025 3:05 PM CST - Business Wire Biote Reports First Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2025. Biotes first quarter results benefited from efficiencies related to the vertical integration of our 503B manufacturing facility as well as growth in our dietary supplements business, said Bret Christensen, Biote Chief Executi
23-Apr-2025 3:05 PM CST - Business Wire Biote Schedules First Quarter 2025 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be
12-Mar-2025 3:05 PM CST - Business Wire Biote Reports Fourth Quarter and Full Year 2024 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net in
26-Feb-2025 3:05 PM CST - Business Wire Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 12, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conf
12-Nov-2024 3:05 PM CST - Business Wire Biote Reports Third Quarter 2024 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 m
5-Nov-2025 3:05 PM CST - Business Wire Biote Reports Third Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners patients, today announced financial results for the third quarter ended September 30, 2025. When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate growth from new providers, maximize value from our top-tier clinics, and improve our financial performance through gre
22-Oct-2025 3:05 PM CST - Business Wire Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call m
6-Aug-2025 3:05 PM CST - Business Wire Biote Reports Second Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2025. Consistent with our action plan to drive structural and cultural change, Biote initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable
23-Jul-2025 3:05 PM CST - Business Wire Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call ma
7-May-2025 3:05 PM CST - Business Wire Biote Reports First Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2025. Biotes first quarter results benefited from efficiencies related to the vertical integration of our 503B manufacturing facility as well as growth in our dietary supplements business, said Bret Christensen, Biote Chief Executi
23-Apr-2025 3:05 PM CST - Business Wire Biote Schedules First Quarter 2025 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be
12-Mar-2025 3:05 PM CST - Business Wire Biote Reports Fourth Quarter and Full Year 2024 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net in
26-Feb-2025 3:05 PM CST - Business Wire Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call biote Corp. (Nasdaq: BTMD) (Biote or the Company), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 12, 2025, after the close of the market. A conference call to discuss the firms results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conf
12-Nov-2024 3:05 PM CST - Business Wire Biote Reports Third Quarter 2024 Financial Results Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 m
